These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32499238)

  • 1. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
    Maiti A; Rausch CR; Cortes JE; Pemmaraju N; Daver NG; Ravandi F; Garcia-Manero G; Borthakur G; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Kadia TM; Takahashi K; Yilmaz M; Jain N; Kornblau S; Montalban Bravo G; Sasaki K; Andreeff M; Bose P; Ferrajoli A; Issa GC; Jabbour EJ; Masarova L; Thompson PA; Wang S; Konoplev S; Pierce SA; Ning J; Qiao W; Welch JS; Kantarjian HM; DiNardo CD; Konopleva MY
    Haematologica; 2021 Mar; 106(3):894-898. PubMed ID: 32499238
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
    Jamy O; Lin K; Worth S; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R
    Br J Haematol; 2022 Aug; 198(3):e35-e37. PubMed ID: 35509246
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
    Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I
    Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.
    Gangat N; Ilyas R; Johnson IM; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Tefferi A
    Haematologica; 2023 Nov; 108(11):3170-3174. PubMed ID: 36861409
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in acute myeloid leukemia - current and future directions.
    Lachowiez C; DiNardo CD; Konopleva M
    Leuk Lymphoma; 2020 Jun; 61(6):1313-1322. PubMed ID: 32031033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.
    Gangat N; Johnson I; McCullough K; Farrukh F; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Tefferi A
    Haematologica; 2022 Oct; 107(10):2501-2505. PubMed ID: 35770533
    [No Abstract]   [Full Text] [Related]  

  • 8. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
    Bewersdorf JP; Giri S; Wang R; Williams RT; Tallman MS; Zeidan AM; Stahl M
    Haematologica; 2020 Nov; 105(11):2659-2663. PubMed ID: 33131256
    [No Abstract]   [Full Text] [Related]  

  • 9. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
    Wang N; He J; Liu F
    Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
    Steinauer N; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar AA; Saliba AN; Torghabeh M; Litzow MR; Hogan WJ; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Yi CA; Tefferi A; Gangat N
    Haematologica; 2024 Aug; 109(8):2706-2710. PubMed ID: 38546692
    [No Abstract]   [Full Text] [Related]  

  • 11. To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission.
    Sevindik OG; Mergen M; Mergen S; Mutlu YG; Aydın BB; Serin I
    Ann Hematol; 2022 Nov; 101(11):2545-2547. PubMed ID: 35906348
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara F
    Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
    Niswander LM; Chung P; Diorio C; Tasian SK
    Haematologica; 2023 Nov; 108(11):3142-3147. PubMed ID: 37021525
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
    Gangat N; Tefferi A
    Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
    Karrar O; Abdelmagid M; Rana M; Iftikhar M; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Elliott MA; Mangaonkar A; Saliba A; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):E63-E66. PubMed ID: 38100217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis.
    Khanna V; Azenkot T; Liu SQ; Gilbert J; Cheung E; Lau K; Pollyea DA; Traer E; Jonas BA; Zhang TY; Mannis GN
    Leuk Res; 2023 Aug; 131():107331. PubMed ID: 37263072
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 20. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
    Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
    Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.